In January, Jiangsu Hengrui Pharmaceuticals' Tegileridine Fumarate injection, for treating moderate to severe post-op abdominal pain, was approved in China.

On March 6th, Nature Reviews Drug Discovery highlighted recent bispecific antibodies (bsAbs) progress in cancer therapy.

In February, Amgen published a study in Nature Metabolism about AMG 133, a novel molecule with potential for treating obesity.

Tharimmune revealed on their website plans to start a Phase 1 trial for TH104, assessing safety and bioavailability, with early results due Q2 2024.

In February, University of Leicester and Leicester Diabetes Centre experts published a summary of obesity treatments in "International Journal of Obesity," highlighting new drugs inspired by gut incretin hormones.

Gastric Cancer (GC) is a deadly global malignancy with over 1 million new cases in 2022, resulting in 783,000 deaths.

This article provides an interpretation of a review published in the 2021 issue of "Nature Reviews Drug Discovery", which analyzes the history and trends of peptide drug development over the past 100 years.

Upadacitinib acts as an ATP-competitive JAK inhibitor; it competes with ATP and blocks nucleotide binding to inhibit kinase activity and the phosphorylation of downstream effectors.

Cannabinoids can be categorized into three types based on their origin: endocannabinoids, phytocannabinoids, and synthetic cannabinoids.

Apart from the approved ADCs, there are hundreds of ADCs under clinical investigation, covering a increasingly diverse range of targets.

Last year belonged to the realm of Pfizer's COVID-19 small molecule treatments, while this year is dominated by GLP-1 injectable and oral therapies.

In late October, Hengrui and Merck agreed on a €1.4 billion transaction, with a first payment of €160 million. The deal mainly involves Hengrui's self-developed PARP1 inhibitor HRS-1167 and Claudin-18.2 ADC SHR-A1904.